{"generic":"Papaverine Hydrochloride","drugs":["Papacon","Papaverine Hydrochloride","Para-Time S.R.","Pavacot"],"mono":{"0":{"id":"441770-s-0","title":"Generic Names","mono":"Papaverine Hydrochloride"},"1":{"id":"441770-s-1","title":"Dosing and Indications","sub":{"0":{"id":"441770-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Erectile dysfunction:<\/b> initial, 30 mg INTRACAVERNOSAL over 1 to 2 min; may increase to 60 mg according to response<\/li><li><b>Erectile dysfunction:<\/b> (combination therapy) 30 mg papaverine \/ 0.5 to 1 mg phentolamine INTRACAVERNOSAL<\/li><li><b>Erectile dysfunction:<\/b> do not use more than 3 times weekly or 2 days in succession<\/li><li><b>Smooth muscle spasm, visceral:<\/b>  1 to 4 mL IV\/IM (30 mg\/mL) repeated every 3 hrs over 1 to 2 min as needed<\/li><\/ul>"},"1":{"id":"441770-s-1-5","title":"Pediatric Dosing","mono":"not  FDA approved in children"},"3":{"id":"441770-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Angina<\/li><li>Cerebrovascular disease<\/li><li>Ischemic heart disease, acute, Complicated by arrhythmias<\/li><li>Peripheral vascular disease, with vasospasm<\/li><li>Smooth muscle spasm, visceral<\/li><li>Thromboembolic disorder<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Arterial catheter occlusion; Prophylaxis<\/li><li>Bypass transplantation with allogeneic transplant, Graft preservation<\/li><li>Erectile dysfunction<\/li><\/ul>"}}},"3":{"id":"441770-s-3","title":"Contraindications\/Warnings","sub":[{"id":"441770-s-3-9","title":"Contraindications","mono":"<ul><li>complete atrioventricular block; may produce transient ectopic rhythms of ventricular origin (premature beats or paroxysmal tachycardia) (injection)<\/li><li>intracorporeal injection (unapproved use); can result in persistent priapism requiring medical and surgical intervention<\/li><li>large doses; can produce serious arrhythmias by depressing atrioventricular and intraventricular conduction (oral)<\/li><\/ul>"},{"id":"441770-s-3-10","title":"Precautions","mono":"<ul><li>glaucoma<\/li><li>hepatic hypersensitivity (ie, gastrointestinal symptoms, jaundice, eosinophilia, or altered liver function test values) has been reported; discontinue use if occurs<\/li><\/ul>"},{"id":"441770-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Papaverine: C (FDA)<\/li><li>Papaverine: A (AUS)<\/li><\/ul>"},{"id":"441770-s-3-12","title":"Breast Feeding","mono":"Papaverine: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"441770-s-4","title":"Drug Interactions","sub":{"2":{"id":"441770-s-4-15","title":"Moderate","mono":"<ul>Ginkgo (probable)<\/ul>"}}},"5":{"id":"441770-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Tachyarrhythmia<\/li><li><b>Dermatologic:<\/b>Pruritus, Rash<\/li><li><b>Gastrointestinal:<\/b>Abdominal discomfort, Constipation, Diarrhea, Loss of appetite, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Headache, Somnolence, Vertigo<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Acidosis<\/li><li><b>Hepatic:<\/b>Hepatotoxicity<\/li><li><b>Neurologic:<\/b>Raised intracranial pressure<\/li><li><b>Reproductive:<\/b>Priapism (2.68%)<\/li><\/ul>"},"6":{"id":"441770-s-6","title":"Drug Name Info","sub":{"0":{"id":"441770-s-6-17","title":"US Trade Names","mono":"<ul><li>Papacon<\/li><li>Para-Time S.R.<\/li><li>Pavacot<\/li><\/ul>"},"2":{"id":"441770-s-6-19","title":"Class","mono":"Peripheral Vasodilator<br\/>"},"3":{"id":"441770-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"441770-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"441770-s-7","title":"Mechanism Of Action","mono":"Papaverine hydrochloride, a benzylisoquinoline opium alkaloid, relaxes the smooth musculature of large blood vessels including the coronary, peripheral, cerebral and pulmonary arteries. It also stimulates respiration by acting on carotid and aortic body chemoreceptors.<br\/>"},"8":{"id":"441770-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"441770-s-8-24","title":"Distribution","mono":"Protein binding: about 90% <br\/>"},"2":{"id":"441770-s-8-25","title":"Metabolism","mono":"Hepatic <br\/>"},"3":{"id":"441770-s-8-26","title":"Excretion","mono":"<ul><li>Renal<\/li><li>Dialyzable: unknown<\/li><\/ul>"}}},"9":{"id":"441770-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>may give IV or IM<br\/><\/li><li><b>Intravenous<\/b><br\/>must inject slowly over 1-2 min<br\/><\/li><\/ul>"},"10":{"id":"441770-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>hepatic function, vital signs; during treatment<\/li><\/ul>"},"11":{"id":"441770-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/><ul><li>Injection Solution: 30 MG\/ML<\/li><li>Oral Capsule, Extended Release: 150 MG<\/li><\/ul>"},"12":{"id":"441770-s-12","title":"Toxicology","sub":[{"id":"441770-s-12-31","title":"Clinical Effects","mono":"<b>PAPAVERINE\/ETHAVERINE<\/b><br\/>OVERDOSE: nausea, vomiting, weakness, CNS depression, nystagmus, diplopia, diaphoresis, flushing, dizziness, and tachycardia are common. In large overdoses lactic acidosis, respiratory alkalosis, hyperglycemia, and hypokalemia have been reported. ADVERSE EFFECTS: Nausea, anorexia, abdominal discomfort, constipation, diarrhea, malaise, vertigo, headache, flushing, sweating, tachycardia, mild hypotension and sedation. <br\/>"},{"id":"441770-s-12-32","title":"Treatment","mono":"<b>PAPAVERINE\/ETHAVERINE <\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Decontamination: Consider activated charcoal if patient is alert or airway is protected.<\/li><li>Hypotensive episode: Intravenous fluids 10 to 20 mL\/kg. If unresponsive dopamine, norepinephrine, or calcium may be used. Calcium chloride dose 1 g IV over 5 to 10 minutes. Monitor ECG and serum calcium.<\/li><li>Metabolic acidosis: Correct hypotension. For severe acidosis (pH less than 7.1) consider bicarbonate 1 to 2 mEq\/kg.<\/li><li>Heart block: May respond to intravenous calcium (calcium chloride 1 gram IV over 5 to 10 minutes), atropine, isoproterenol, or glucagon (2 to 5 mg IV, initiate continuous infusion if responsive). Insertion of a temporary pacemaker may be needed.<\/li><li>Monitoring of patient: Monitor vital signs. Institute continuous cardiac monitoring and obtain an ECG. Monitor serum electrolytes. Monitor arterial blood gases in patients with metabolic acidosis or respiratory symptoms.<\/li><\/ul>"},{"id":"441770-s-12-33","title":"Range of Toxicity","mono":"<b>PAPAVERINE\/ETHAVERINE<\/b><br\/>OVERDOSE: ORAL: 15 g produced severe acidosis in an adult; doses of 1 g produced minimal toxicity. INTRAVENOUS: doses of 30 and 65 milligrams caused the death of 2 adults which was preceded by hyperpnea, tachypnea, and apnea. THERAPEUTIC: ORAL 150 milligrams extended release every 12 hours, doses up to 300 mg extended release every 12 hours used in refractory cases: INTRAVENOUS: doses of 30 to 120 mg every 3 hours as needed. <br\/>"}]},"13":{"id":"441770-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause tachyarrhythmia, abdominal discomfort, constipation, diarrhea, anorexia, nausea, vomiting, headache, somnolence, and vertigo.<\/li><li>Advise patient to report priapism or signs\/symptoms of hepatotoxicity.<\/li><\/ul>"}}}